Literature DB >> 24821360

The role of dopamine D₁ and D₂ receptors in adolescent methylphenidate conditioned place preference: sex differences and brain-derived neurotrophic factor.

Elizabeth D Cummins1, Stephen B Griffin, Chase M Duty, Daniel J Peterson, Katherine C Burgess, Russell W Brown.   

Abstract

This study analyzed the role of dopamine D1 and D2 receptors in methylphenidate (MPH) conditioned place preference (CPP) in adolescent male and female rats, in addition to the role of these receptors in the effects of MPH on brain-derived neurotrophic factor (BDNF) in the dorsal striatum and nucleus accumbens. Using a nonbiased CPP procedure, the animals were conditioned from postnatal day (PD) 33 to 37. On conditioning trials, animals were first administered saline or their respective antagonist (0.1 or 0.2 mg/kg SCH-23390; 0.01 or 0.03 mg/kg eticlopride HCl), followed by MPH (5 mg/kg). Approximately 10 min after MPH administration, the rats were placed into the paired context for a 10-min trial. One day after conditioning on PD38, a preference test was administered with dividers removed. One day following the preference test on PD39, brain tissue was removed, and the nucleus accumbens and striatum were analyzed for BDNF. Results revealed that MPH conditioning resulted in an increased preference that was blocked by either dose of SCH-23390, but generally not affected by either dose of eticlopride. Further, the higher dose of SCH-23390 resulted in a conditioned place aversion in males, presumably due to an increased number of dopamine D1 receptors in adolescent males. MPH produced a significant increase of striatal and accumbal BDNF alleviated by SCH-23390 or eticlopride. These results show that MPH results in CPP in adolescent male and female rats and these effects appear to be mediated by the dopamine D1 receptor, but the effects of MPH on BDNF appear to be mediated by both dopamine receptor families.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24821360     DOI: 10.1159/000360636

Source DB:  PubMed          Journal:  Dev Neurosci        ISSN: 0378-5866            Impact factor:   2.984


  6 in total

1.  Acute and long-term effects of adolescent methylphenidate on decision-making and dopamine receptor mRNA expression in the orbitofrontal cortex.

Authors:  Leslie R Amodeo; Eliza Jacobs-Brichford; Matthew S McMurray; Jamie D Roitman
Journal:  Behav Brain Res       Date:  2017-02-14       Impact factor: 3.332

2.  Effect of Chronic Methylphenidate Treatment in a Female Experimental Model of Parkinsonism.

Authors:  Hannah V Oakes; David McWethy; Shannon Ketchem; Lily Tran; Kaitlyn Phillips; Laura Oakley; Richard J Smeyne; Brooks B Pond
Journal:  Neurotox Res       Date:  2021-03-05       Impact factor: 3.911

3.  PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.

Authors:  Tyler Stevens; Katrin Sangkuhl; Jacob T Brown; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-08       Impact factor: 2.089

4.  In vivo imaging of dopamine D1 receptor and activated microglia in attention-deficit/hyperactivity disorder: a positron emission tomography study.

Authors:  Masamichi Yokokura; Kiyokazu Takebasashi; Akiyo Takao; Kyoko Nakaizumi; Etsuji Yoshikawa; Masami Futatsubashi; Katsuaki Suzuki; Kazuhiko Nakamura; Hidenori Yamasue; Yasuomi Ouchi
Journal:  Mol Psychiatry       Date:  2020-05-21       Impact factor: 15.992

5.  The effect of a dopamine antagonist on conditioning of sexual arousal in women.

Authors:  Mirte Brom; Ellen Laan; Walter Everaerd; Philip Spinhoven; Baptist Trimbos; Stephanie Both
Journal:  Psychopharmacology (Berl)       Date:  2016-02-02       Impact factor: 4.530

6.  Single exposure of dopamine D1 antagonist prevents and D2 antagonist attenuates methylphenidate effect.

Authors:  Catherine M Claussen; Lindsey J Witte; Nachum Dafny
Journal:  J Exp Pharmacol       Date:  2015-04-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.